Omada Health CEO Sean Duffy sells $248,730 in company shares
At a glance
- $OMDA today−20.4%last $15.09
- 52-week range46.8% above low$10.28 – $25.45
- In the headline$248,730Amount
- Coverage1 this week1 in 30 days · thin coverage — a small sample
- Sector scannerCalmHealth Care
What it means
- What to watch: This one turns on a concrete figure ($248,730); set it against the recent trend before reading it as a turning point.
- How the stock is trading: $OMDA -20.37% in the latest session.
- Timing: Weekend news: the change beside it is Friday's, and Monday's open is the first session that gets a say. Market holidays are not detected.
Where the stock stands
$OMDA last traded at $15.09, -20.37% on the session. That puts it 41% shy of its 52-week high of $25.45 and 47% clear of its low of $10.28 — a little below the middle of the range. Over the year it has ranged 148% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $OMDA page.
How much coverage it is getting
This is the only story Wook has logged on $OMDA in the last 30 days — a quiet name that just got a headline. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
What to watch next
For the receipts, the $OMDA page has the full chart, the filings and the valuation model these figures come from. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $OMDA is from its high, or how this week's coverage compares.
Discussion
No one has weighed in yet. Start the discussion on this story.